Glaxo inks licensing agreement with Astellas

The research-based pharmaceutical healtcare company GlaxoSmithKline (GSK) has tied up with Japanese company Astellas Pharma for exclusive rights of its research product by the brand name Mycamine.

The tie-up is said to assert GSK's presence in the intensive care. The injectbale anti-fungal agent Micafungin  is approved by many countries across the world. Micafungin belongs to a new class of anti-fungal agents that work against deep seated Candida infections.

The agreement is in line with the company's strategy to partner with global pharmaceutical companies for licensing in important molecules.

Ravi Limaye, vice-president, pharmaceuticals, GSK India added, "Micafungin also provides an excellent fit with oncology where GSK has a promising R&D pipeline."